Compare
Viskase Holdings, Inc. vs Windtree Therapeutics Inc vs Scilex Holding Co vs Monte Rosa Therapeutics, Inc.
| Latest fiscal year | Viskase Holdings, Inc. VISKRevenue covers only part of its income (partial revenue) | Windtree Therapeutics Inc WINTLast annual report: year ended 2024-12-31 | Scilex Holding Co SCLXRevenue covers only part of its income (partial revenue) | Monte Rosa Therapeutics, Inc. GLUE |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2024-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $30.25M | $123.67M |
| Revenue growth (YoY) | n/a | n/a | -46.5% | +63.5% |
| Gross margin | n/a | n/a | 65.0% (computed) | n/a |
| Operating margin | n/a | n/a | n/m | -43.8% |
| Net margin | n/a | n/a | n/m | -31.2% |
| Net income | -$3.41M | -$1.79M | -$374.05M | -$38.63M |
| EPS (Diluted) | -$0.07 | n/a | -$36.48 | n/a |
| Operating cash flow | -$3.01M | -$15.40M | $3.82M | -$22.80M |
| Free cash flow | n/a | -$15.41M | $3.68M | -$27.50M |
| Cash & equivalents | $42.57M | $1.78M | $4.96M | $129.88M |
| Total assets | $42.81M | $27.88M | $364.98M | $448.66M |
| Total liabilities | n/a | $14.70M | $576.73M | $215.60M |
| Shareholders' equity | -$2.52M | $10.00M | -$207.78M | $233.06M |
| Return on year-end equity | n/a | -17.9% | n/a | -16.6% |
| Shares outstanding | 74.21M | 256.4K | 7.03M | 65.54M |
Revenue, most recent five fiscal years
| Fiscal year | Viskase Holdings, Inc. | Windtree Therapeutics Inc | Scilex Holding Co | Monte Rosa Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $198.0K Ended 2019-12-31 | n/a | $123.67M Ended 2025-12-31 |
| 1 year earlier | n/a | $1.79M Ended 2018-12-31 | n/a | $75.62M Ended 2024-12-31 |
| 2 years earlier | n/a | $1.49M Ended 2017-12-31 | n/a | $0 Ended 2023-12-31 |
| 3 years earlier | n/a | $2.04M Ended 2016-12-31 | n/a | n/a |
| 4 years earlier | n/a | $987.0K Ended 2015-12-31 | n/a | n/a |